Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
17 08 2023
Historique:
medline: 21 8 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.

Identifiants

pubmed: 37595560
pii: S0092-8674(23)00809-7
doi: 10.1016/j.cell.2023.07.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3523-3523.e1

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Alberto L Epstein (AL)

EG427 Paris, France. Electronic address: alberto@eg427.com.

Cornelia Haag-Molkenteller (C)

EG427 Paris, France. Electronic address: cornelia@eg427.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH